Summary
AI response content provided in the prompt is a single-label evaluation about increased all-cause mortality; the supplied prescribing information excerpt supports this mortality claim. However, the prompt also includes multiple additional tigecycline claims that are not evaluated/answered by the AI response, making the overall alignment incomplete relative to the broader set of claims.
Category Scores
Accurate Statements
An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in TYGACIL-treated patients versus comparator.
Supported by labeling excerpt in the Boxed Warning/Warning and Precautions: “An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in TYGACIL-treated patients versus comparator.”
Unsupported Statements
The claim 'evaluation': 'supported' and 'verdict': 'adheres_to_label' for the mortality statement.
While the specific mortality statement is supported, the AI response does not address the other claims included in the prompt; as a whole, the response is not a complete alignment evaluation for the entire claim set.
Contradictions
Important Omissions
No evaluation provided for the remaining included claims (e.g., indications for complicated skin/intra-abdominal infections and CAP pneumonia; microbiology activity claims; cure-rate and MIC-related statements; blood concentration characterization; monotherapy/bacteremia management; explicit comparison details for black-box risk percentage; and comparisons to colistin/other antimicrobials; patent/exclusivity and sourcing claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Only the boxed warning mortality statement was evaluated, and it is consistent with the provided labeling excerpt. The risk is limited to completeness of alignment rather than a direct contradiction of label safety content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Incomplete
Primary Issue
AI response only addresses a single mortality claim and does not evaluate the remainder of the claims provided in the prompt against the label.
Suggested Improvement
Evaluate each provided claim item-by-item against the supplied prescribing information, and report unsupported/contradictory statements and material omissions for the full set.